Raj Singh1, Jan Jenkins2, Joanne Davis2, Shiyu Song1, Sanjeev Sharma3, John Austin Vargo4. 1. Virginia Commonwealth University Health System, Department of Radiation Oncology, Richmond, VA, USA. 2. The Radiosurgery Society, Sunnyvale, CA, USA. 3. St. Mary's Medical Center, Department of Radiation Oncology, Huntington, WV, USA. 4. University of Pittsburgh Hillman Cancer Center, Department of Radiation Oncology, Pittsburgh, PA, USA.
Abstract
Background: There is limited data on clinical outcomes following SBRT for patients with metastatic head and neck squamous cell carcinoma (mHNC). Method: An international SBRT registry was utilized to identify patients. LC and OS were evaluated with the Kaplan-Meier method and a Cox-proportional hazards model for multivariate analysis (MVA) to assess potential prognostic factors. Results: We identified 81 patients with 98 lesions treated with SBRT. Areas treated included the lung (53.0%), non-regional lymph nodes (16.0%), and spine (12.3%). OS rates at 1 year and 2 years were 66.4% and 43.1%, respectively. Utilizing KPS, spinal disease, and GTV, 1-year OS estimates were 90.9%, 70.4%, 54.5%, and 25% for patients with 0-3 of these factors, respectively (p = 0.002). One-year and 2-year LC rates were both 93.3%. Roughly 17% of patients reported toxicities (none Grade 3+). Conclusions: SBRT resulted in promising LC for mHNC patients. Spinal disease, GTV, and KPS should be considered in selecting patients with mHNC that may benefit from SBRT.
Background: There is limited data on clinical outcomes following SBRT for patients with metastatic head and neck squamous cell carcinoma (mHNC). Method: An international SBRT registry was utilized to identify patients. LC and OS were evaluated with the Kaplan-Meier method and a Cox-proportional hazards model for multivariate analysis (MVA) to assess potential prognostic factors. Results: We identified 81 patients with 98 lesions treated with SBRT. Areas treated included the lung (53.0%), non-regional lymph nodes (16.0%), and spine (12.3%). OS rates at 1 year and 2 years were 66.4% and 43.1%, respectively. Utilizing KPS, spinal disease, and GTV, 1-year OS estimates were 90.9%, 70.4%, 54.5%, and 25% for patients with 0-3 of these factors, respectively (p = 0.002). One-year and 2-year LC rates were both 93.3%. Roughly 17% of patients reported toxicities (none Grade 3+). Conclusions: SBRT resulted in promising LC for mHNC patients. Spinal disease, GTV, and KPS should be considered in selecting patients with mHNC that may benefit from SBRT.
Authors: Dario Pasalic; Sonia L Betancourt-Cuellar; Nicolette Taku; Ethan B Ludmir; Yi Lu; Pamela K Allen; Chad Tang; Mara B Antonoff; Clifton D Fuller; David I Rosenthal; William H Morrison; Jack Phan; Adam S Garden; James W Welsh; Joe Y Chang; Zhongxing Liao; Jeremy J Erasmus; Quynh-Nhu Nguyen Journal: Head Neck Date: 2020-03-04 Impact factor: 3.147
Authors: David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan Journal: Lancet Date: 2019-04-11 Impact factor: 79.321
Authors: Sean McBride; Eric Sherman; C Jillian Tsai; Shrujal Baxi; Jahan Aghalar; Juliana Eng; Wanqing Iris Zhi; Daniel McFarland; Loren Scott Michel; Robert Young; Robert Lefkowitz; Daniel Spielsinger; Zhigang Zhang; Jessica Flynn; Lara Dunn; Alan Ho; Nadeem Riaz; David Pfister; Nancy Lee Journal: J Clin Oncol Date: 2020-08-21 Impact factor: 44.544